Quantitative magnetic resonance techniques as surrogate markers of Alzheimer's disease.
Quantitative magnetic resonance techniques as surrogate markers of Alzheimer's disease.
复制标题
DOI：
10.1602/neurorx.1.2.196
复制
发表时间：
2004-04-01
期刊：
影响因子：
--
通讯作者：
Jack, Clifford R Jr
中科院分区：
文献类型：
--
作者：
Kantarci, Kejal;Jack, Clifford R Jr
了解阿尔茨海默氏病分子生物学（AD）的最新进展为可预见的将来提供了有用的治疗干预的希望。因此，改进的早期诊断方法和AD疾病严重程度的无创替代物变得更加急切。各种定量磁共振（MR）技术测量了解剖学，生化，微结构，功能和血液流量变化，以作为可能的疾病进展的替代测量。横截面和纵向研究表明，基于MR的体积测量是从临床前阶段开始的AD疾病进展的潜在替代物。基于MR的体积作为AD治疗疗效的替代标记的有效性仍有待测试在阳性疾病改良的药物试验中。在正电子发射断层扫描的淀粉样成像示踪剂的最新发展一直是AD成像标记领域的主要突破。在MR成像中也正在进行图像斑块的努力。与间接的MR度量一样，这些直接成像病理底物的方法将需要通过纵向研究进行验证过程，以证明其作为AD中的替代标记的有用性。
Recent advances in understanding the molecular biology of Alzheimer's disease (AD) offer the promise of useful therapeutic intervention in the foreseeable future. Hence, improved methods for early diagnosis and noninvasive surrogates of disease severity in AD have become more imperative. Various quantitative magnetic resonance (MR) techniques that measure the anatomic, biochemical, microstructural, functional, and blood-flow changes are being evaluated as possible surrogate measures of disease progression. Cross-sectional and longitudinal studies indicate that MR-based volume measurements are potential surrogates of disease progression in AD, starting from the preclinical stages. The validity of MR-based volumetry as a surrogate marker for therapeutic efficacy in AD remains to be tested in a positive disease-modifying drug trial. Recent development of amyloid imaging tracers for positron emission tomography has been a major breakthrough in the field of imaging markers for AD. Efforts to image plaques are also underway in MR imaging. As with indirect MR measures, these approaches of directly imaging the pathological substrate will need to undergo a validation process with longitudinal studies to prove their usefulness as surrogate markers in AD.